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Objective: To compare the incidence of neonatal group B streptococcus (GBS) infection in active GBS
carriers with preterm prelabor rupture of membranes (PPROMs) after penicillins and erythromycin
prophylaxis.
Materials and methods: Patients diagnosed to have PPROM between 2004 and 2009 inclusive were
treated using erythromycin (erythromycin group), ampicillin, amoxicillin or co-amoxiclav (penicillin
group), or no antibiotics (control group) according to department protocols depending on their gestation
and their GBS status at the time of presentation. Patients receiving both erythromycin and penicillins
were included in the penicillin group. The incidence of neonatal GBS infection was compared between
groups categorized according to the antibiotic regime received.
Results: A total of 680 women were diagnosed to have PPROM of which 85 (12.5%) were active GBS
carriers. GBS isolates were 100% sensitive to penicillins but only 35% were sensitive to erythromycin.
There were 16, 22, and 47 patients in the penicillin, erythromycin, and control groups, respectively. The
incidence of neonatal GBS infection in the three groups was 0%, 36%, and 13%, respectively, and was
statistically signiﬁcant (p ¼ 0.023).
Conclusion: Penicillins are more effective than erythromycin in preventing neonatal GBS infection in
womenwith PPROMwho were active GBS carriers. Because most women do not know their GBS status at
the time of PPROM and it is practically difﬁcult to identify the active carriers before delivery, ampicillin/
amoxicillin should be used as a prophylactic antibiotic for active GBS carriers and women with unknown
GBS carriage status to prevent neonatal GBS infection following PPROM.
Copyright © 2014, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction
Preterm prelabor rupture of membranes (PPROMs) complicates
2e3% of pregnancy and accounts for 40% of preterm deliveries [1].
PPROM is associated with serious neonatal morbidity andmortality
because of prematurity, infection, and prolonged oligohydramnios.
Infection can either be the cause or a consequence of PPROM. It has
been reported that positive amniotic ﬂuid cultures are detected in
32.4% of patients and that 25e29% of patients diagnosed with
PPROM developed clinical chorioamnionitis before delivery [2,3].
Chorioamnionitis itself can cause neonatal sepsis, intracranialand Gynaecology, Prince of
Shatin, New Territories, Hong
ng).
bstetrics & Gynecology. Publishedhemorrhage, respiratory distress syndrome, and cerebral palsy
[4,5]. A meta-analysis has shown that using erythromycin or pen-
icillins as the empirical antibiotics following PPROM is associated
with a signiﬁcant reduction in chorioamnionitis [risk ratio (RR):
0.66; 95% conﬁdence interval (CI): 0.46e0.96] and delivery before
48 hours (RR: 0.71; 95% CI: 0.58e0.87) and 7 days (RR: 0.79; 95% CI:
0.71e0.89) [6]. In the ORACLE I trial, erythromycinwas shown to be
associated with a range of health beneﬁts for the neonate, whereas
co-amoxiclav was demonstrated to be associated with increased
number of necrotizing enterocolitis (NEC) [1]. Erythromycin is
therefore preferred to co-amoxiclav as the ﬁrst-line regime in the
guidelines of some professional bodies [7,8]. However, although
erythromycin is a broad-spectrum antibiotic, it is less effective at
treating group B streptococcus (GBS) infections, which remains as
the predominant pathogen in causing early onset neonatal sepsis,
due to the insensitivity of the GBS bacterium in some patients [9].by Elsevier Taiwan LLC. All rights reserved.
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nant women [10e12]. Although universal antenatal screening of
GBS has been implemented in Hong Kong, it is performed at 35e37
weeks and the GBS carriage status is usually not known at the time
when a woman presents with PPROM. As the bacterial culture
usually takes a few days to perform, it would mean that in some
pregnancies it is too late to change to an appropriate prophylactic
antibiotic against GBS should the culture indicate insensitivity to
erythromycin.
The aim of this study was to investigate the prevalence of GBS
colonization among women presenting with PPROM, and to assess
the effectiveness of different antibiotic treatments in preventing
neonatal GBS infection following PPROM among the active GBS
carriers.
Materials and methods
A retrospective cohort study was performed to identify women
having a singleton pregnancy diagnosed with PPROM before 37
weeks of gestation and who delivered between 24 and 36þ6 weeks
from January 1, 2004, to December 31, 2009, in the Prince of Wales
Hospital. Data were extracted from the patients'medical notes and
institutional computerized obstetric database. The study was
approved by the Institutional Investigation Ethics Review Board.
Women were diagnosed to have PPROM based on clinical his-
tory and sterile speculum examination demonstrating the presence
of amniotic ﬂuid in the vagina. If the speculum examination was
equivocal, a test was performed to conﬁrm PPROM by detecting the
presence of insulin-like growth factor binding protein-1 in vaginal
ﬂuid sample using a commercial test kit (Actim PROM, Laboratorios
Rubio, S.A., Barcelona, Spain). Womenwho were diagnosed to have
PPROM before 34 weeks of gestation and who were not in active
labor and showed no clinical evidence of chorioamnionitis or
placental abruption were admitted for expectant management in
accordance with our department protocol. Women were managed
under this protocol as follows:
 Four doses of 6-mg dexamethasone to be given intramuscularly
every 12 hours.
 Prophylactic antibiotic to be given for 10 days or until delivery,
whichever occurred earlier.
B 250mg erythromycin to be given orally four times daily if the
patient was not known to be a GBS carrier.
B 2 g ampicillin to be given intravenously as a loading dose,
followed by 250 mg oral amoxicillin, three times daily
instead of giving erythromycin if the patient was known to be
a GBS carrier.
B 900 mg clindamycin to be given intravenously for loading,
followed by 250 mg oral erythromycin, four times daily if the
patient was known to be a GBS carrier, but was allergic to
penicillins.
 A high vaginal swab andmidstream urine sample to be taken for
bacterial culture and subsequent treatment to be given ac-
cording to the culture result. Women treated by erythromycin
are to be changed to amoxicillin if the GBS culture is positive and
the GBS isolate is erythromycin resistant.
 The patient to be kept in hospital for observation for any clinical
sign or symptom of chorioamnionitis. If chorioamnionitis is
suspected, prompt delivery is advised.
 If there is no clinical evidence of chorioamnionitis or preterm
labor, induction of labor is to be planned at 34 weeks by
oxytocin infusion. Cesarean section should be performed based on obstetric
indication.
 Placental swab is to be taken for bacterial culture and the
placenta is to be sent for histology.
 If the patient had PPROM after 34 weeks, induction of labor is to
be advised after 24 hours following the ROMs. No prophylactic
antibiotic is required except in patients who are known GBS
carriers who should be given 2 g ampicillin intravenously fol-
lowed by 1 g every 6 hours until delivery occurs.
In this study, patients with positive maternal or neonatal GBS
culture after PPROM were regarded as active GBS carriers. Women
who were known to be GBS carriers with positive GBS culture in
early pregnancy or previous pregnancy or history of neonatal GBS
infection in the past, but were found to be GBS culture negative
upon admission for PPROM were not classiﬁed as active GBS
carriers.
Babies were deﬁned as having neonatal GBS infection if they had
a positive GBS culture from either blood, cerebrospinal ﬂuid, um-
bilical cord, ear, eye, or nose together with raised C-reactive protein
(CRP) >10 in the ﬁrst 7 days of life. If CRP was not raised, it was
classiﬁed as neonatal colonization.
The patients identiﬁed to be active GBS carriers were classiﬁed
into three groups, namely, erythromycin, penicillin, and control (no
antibiotic received) for statistical analysis. The penicillin group
included women who either only received penicillins or who were
switched from erythromycin to penicillins because the bacterial
culture indicated that they were resistant to erythromycin. Those
with PPROM who were negative for GBS cultures were not further
analyzed in this study. The differences in categorical outcomes
between the three groups were tested for signiﬁcance using the
Chi-square test for independence and Fisher's exact probability test.
Difference between continuous variables was tested for signiﬁ-
cance using the independent-samples t test and one-way analysis
of variance.
Statistical analysis was performed using PASW Statistic 18 (SPSS
Inc, Chicago, IL, USA). All hypothesis tests were two sided and
p < 0.05 was considered statistically signiﬁcant.Results
There were 37,138 women who had a singleton pregnancy and
delivered in our unit between January 2004 and December 2009.
Among these deliveries, 680 (1.8%) deliveries were from women
who were conﬁrmed to have PPROM. Table 1 summaries the
maternal and clinical details of the 85 women (13%) who were
found to have a positive GBS culture results after admission (active
carrier), categorized according to the treatment received.
A total of 72 of the 85 women who were active carriers (85%)
were only identiﬁed after delivery as the bacterial culture results
were only available 2e5 days after their admission. In the
remaining 13 (15%) women who were known GBS carriers before
delivery, seven were newly diagnosed after PPROM, whereas six
had known history of GBS carriage before PPROM. These six cases
accounted for 16% of all 38 cases with a previous history of GBS
colonization before PPROM (Fig. 1).
The antibiotic susceptibility test results of the GBS culture were
available in 80 of the 85 cases of active carriers. The antibiotic
susceptibility test results of the remaining ﬁve cases were not
known as the swabs were taken in the private sector and the in-
formation about the antibiotic sensitivity was missing in the case
notes. Fifty-two (65%) of the GBS isolates were resistant to eryth-
romycin and 100% of themwere sensitive to penicillins. The overall
incidence of neonatal GBS infection in women diagnosed with
Table 1
Patients' baseline characteristics.
(I) (II) (III) p
Penicillin (n ¼ 16) Erythromycin (n ¼ 22) Control (n ¼ 47) I versus II
versus III
I versus II I versus III II versus III
Maternal age (mean ± SD) 31.9 ± 4.2 33.4 ± 6.1 31.87 ± 6.0 0.562 0.697 1.000 0.558
Nulliparity 9 (56.3) 7 (31.8%) 26 (55.4%) 0.160 0.132 0.948 0.069
Gestational age at ROM (wk, mean ± SD) 32.2 ± 3.8 29.6 ± 2.8 35.3 ± 2.5 <0.001 0.019 0.001 <0.001
ROM before 34 wk 10 (62.5%) 21 (95.5%) 5 (10.6%) <0.001 0.028 <0.001 <0.001
Latency from ROM to delivery >48 h 7 (43.8%) 14 (63.6%) 2 (4.3%) <0.001 0.224 0.001 <0.001
Latency from ROM to delivery (h, mean ± SD) 168.4 ± 277.7 192.1 ± 293.0 21.6 ± 13.8 <0.001 0.925 0.025 0.002
Gestational age at delivery (wk, mean ± SD) 34.2 ± 4.3 30.8 ± 2.5 35.4 ± 2.5 <0.001 0.001 0.392 <0.001
GBS status
Known before ROM 6 (37.5%) 0 0 <0.001 0.003 <0.001 NA
Known after ROM but before delivery 5 (31.3%) 2 (9.1%) 0 <0.001 0.108 0.001 0.098
Known after delivery 5 (31.3%) 20 (90.9%) 47 (100%) <0.001 <0.001 <0.001 0.098
GBS ¼ group B streptococcus; N/A ¼ not available; ROM ¼ rupture of membranes; SD ¼ standard deviation.
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carriers.
Sixteen women received penicillins of whom six were known
GBS carriers. These six women received ampicillin on admission in
accordance with our unit's management protocol. Five women
initially received erythromycin and were subsequently changed to
ampicillin before delivery as their high vaginal swab test results
showed positive GBS culture. The remaining ﬁve cases were given
co-amoxiclav because of maternal fever.
The erythromycin group consisted of 22 cases. Twenty one had
PPROM before 34 weeks without knowing their GBS carriage status
before delivery, and were therefore given erythromycin in accor-
dance with our management protocol. Among these 21 women,
two were subsequently conﬁrmed to have positive GBS culture
before delivery, but their GBS isolates were sensitive to erythro-
mycin and theywere not switched to penicillins. The remaining one
patient was given erythromycin because of a recent Chlamydia
infection.
There were 47 women included in the control group, of which
42 did not receive any antibiotic as they had PPROM after 34 weeksFig. 1. Patients' proﬁle. GBS ¼ group B streptococcus; Pand were not known to be GBS carriers before delivery. The
remaining ﬁve women had PPROM before 34 weeks of gestation
and delivered shortly after admission before antibiotics could be
given. All these ﬁvewomen had an unknown GBS status at the time
of delivery. There was no statistically signiﬁcant difference in the
parity and maternal age among the three groups. However, sig-
niﬁcant differences were observed among the groups regarding the
gestation at ROMs, latency from ROM to delivery, and gestation at
delivery. The gestation at ROM and at delivery was larger in the
control group as most patients with PPROM after 34 weeks were
not given antibiotics according to the protocol. The latency from
ROM to delivery was shorter in the control than in the other two
groups that received antibiotics, because those patients with
PPROM after 34 weeks would have planned delivery shortly after
admission. By contrast, most patients in the antibiotics-receiving
groups were admitted before 34 weeks and conservative manage-
ment would be adopted up to 34 weeks. All women who received
erythromycin had PPROM before 34 weeks (except one case of
Chlamydia infection), but those women with a known history of
GBS colonization were given ampicillin/amoxicillin regardless ofPROM ¼ preterm prelabor rupture of membrane.
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group was signiﬁcantly larger than the erythromycin group.
Table 2 presents the comparison of the neonatal outcomes be-
tween the three groups. There were signiﬁcantly less neonatal GBS
colonization in the penicillin group (19%) in comparison with the
erythromycin group (64%; p ¼ 0.009) and the control group (49%;
p ¼ 0.043). Our study also showed that the antibiotics in the
penicillin group were signiﬁcantly more effective in preventing
neonatal GBS infection than erythromycin (0% vs. 36%; p ¼ 0.012).
When comparing with the control group, neonatal GBS infection
rate was also higher in the erythromycin group (36% vs. 13%;
p ¼ 0.023). The culture results revealed that the GBS isolates were
erythromycin resistant in 88% (7/8) of the infected neonates in the
latter group. There were one and four perinatal deaths in the
erythromycin group (5%) and the control group (9%), respectively.
Table 3 summarizes the details of the cases of perinatal death. The
GBS isolate in the case of perinatal death in the erythromycin group
was also erythromycin resistant. All except one of the deaths were
related to GBS sepsis. The cause of death of the remaining case was
due to Edward syndrome. The baby was born with multiple
anomalies including absent right ear canal, cleft lip, cleft palate,
bilateral hypoplastic radius, bilateral undescended testes, absent
left kidney, hemivertebrae, large ventricular septal defect, patent
ductus arteriosus, coarctation of aorta, and esophageal atresia. The
diagnosis of Edward syndrome was subsequently conﬁrmed by
genetic study. No neonatal death was identiﬁed in the penicillin
group, although the difference in mortality rates between the three
groups did not reach statistical signiﬁcance. No case of NEC was
observed in our study.
Discussion
The incidence of PPROM during the period between 2004 and
2009 was 1.8%, which is comparable to the rate reported in the
literature [1]. GBS colonization inpatientswith PPROMwas common
(13%) and the overall incidence of neonatal GBS infection (16%) and
perinatal mortality (5%) among the GBS carriers was high. It is
important for us to know whether our current management in
PPROM is effective in reducing the neonatalmortality andmorbidity.
In a large systematic review of 22 trials involving over 6000
women with PPROM, beneﬁts were observed in trials using peni-
cillins and erythromycin in terms of prolongation of pregnancy and
reduction in neonatal morbidity, including neonatal infection [6].
However, there was no analysis with regard to the effect of any
particular antibiotic in preventing neonatal GBS infection inwomen
with PPROM. It has been found that when penicillin, ampicillin, or
cefazolin prophylaxis was administered for more than 4 hours
before delivery to GBS-colonized women delivering before 37
weeks, antibiotic prophylaxis was 78% effective in preventing early
onset GBS disease. No data were available on the effectiveness of
antibiotics given before the intrapartum period in GBS-colonized
women with PPROM for preventing neonatal GBS sepsis [13].
Therefore, the optimal antibiotic regimen is unclear, exceptTable 2
Neonatal outcomes.
(I) (II) (III)
Penicillin (n ¼ 16) Erythromycin (n ¼ 22) Cont
Neonatal GBS colonization 3 (18.8%) 14 (63.6%) 23 (4
Neonatal GBS infection 0 8 (36.4%) 6 (1
Neonatal death 0 1 (4.5%) 4 (8
GBS ¼ group B streptococcus.
a One of the deaths was due to Edward syndrome.avoiding co-amoxiclav because of increased risk of NEC [1,6]. In our
study, we clearly demonstrated that penicillins are superior to
erythromycin in preventing neonatal GBS infection in mothers who
were active GBS carriers. This result was likely related to the high
erythromycin resistant rate in our locality. In the United States,
Panda et al also observed an increase in erythromycin resistance
(25.5%) in their institution [14]. Because GBS sensitivity data are
unique to individual institutions, each unit should have their own
periodic assessment of antibiotic resistance among its patients. The
fact that the neonatal GBS infection rate of the erythromycin group
was higher than the control group may be related to the longer
latency period of the erythromycin group [15].
The major concern of the use of broad-spectrum penicillins is
the increase in the risk of NEC. However, currently only co-
amoxiclav had been found to be associated with neonatal NEC
[1]. A previous small randomized controlled trial involving the use
of antepartum ampicillin in patients with PPROM found no differ-
ence in the incidence of neonatal NEC between the treatment group
(0%, N ¼ 8) and the placebo group (14%, N ¼ 7) [16]. Another ran-
domized, placebo-controlled trial of over 600 women with PPROM
found that the combination of ampicillin and erythromycin
decreased the likelihood of NEC (2.3% vs. 5.8%, p ¼ 0.03) [17].
Therefore, ampicillin appears to be safe for antenatal use. The other
concern about using broad-spectrum antibiotics such as ampicillin
is the emergence of antibiotic resistance. To minimize such risk, the
use of ampicillin could be conﬁned to women who had PPROM or
known history of GBS. During the period of study, all cases of GBS
identiﬁed in our unit were sensitive to penicillins. Further studies
and continued vigilance will be necessary to ensure that this con-
tinues to be the case. Amoxicillin and ampicillin are amino-
penicillins with similar antibacterial spectrums and both are much
cheaper than penicillin G, which is recommended by The Royal
College of Obstetricians and Gynaecologists [7].
To avoid unnecessary use of penicillins in PPROM, the alterna-
tive is to conﬁrm or exclude the GBS carrier status by rapid testing
for GBS. More and more rapid tests for GBS have been developed,
including polymerase chain reaction, optical immunoassay, DNA
hybridization, enzyme immunoassay, and latex agglutination [18].
The rapid tests can overcome the problem of slow reporting time of
the traditional bacterial culture, thereby allowing obstetricians to
give appropriate antibiotic treatment accordingly. This could pre-
vent the risk of overtreating mothers with broad-spectrum anti-
biotics. However, the rapid tests are costly and not readily available
in our clinical setting. Before the rapid tests become readily avail-
able, it is practically difﬁcult to identify the active carriers before
delivery, and ampicillin/amoxicillin appeared to be a better pro-
phylactic antibiotic for women presenting with PPROM to prevent
neonatal GBS infection if the GBS carriage status is unknown.
The main limitation of our study is its small sample size, and
therefore we could not demonstrate any statistic signiﬁcance in
neonatal GBS infection between the penicillin group and the con-
trol group (0% vs. 13%; p ¼ 0.324). Nonetheless, there was signiﬁ-
cantly less neonatal GBS colonization. Our data indicate that thep
rol (n ¼ 47) I versus II versus III I versus II I versus III II versus III
8.9%) 0.022 0.009 0.043 0.254
2.8%) 0.007 0.012 0.324 0.023
.5%)a 0.437 1.000 0.564 1.000
Table 3
Details of the cases of neonatal death.
Case Gestation
of PPROM
Gestation
at delivery
Antibiotic given GBS status Age at
perinatal death (d)
Neonatal GBS
colonization
Neonatal GBS
infection
Suspected cause
of death
1 28 30 Erythromycin Known after delivery 43 Yes Yes GBS sepsis
2 35 35 None Known after delivery 9 Yes Yes GBS sepsis
3 36 36 None Known after delivery 5 Yes Yes GBS sepsis
4 36 36 None Known after delivery 8 Yes Yes GBS sepsis
5 32 32 None Known after delivery 6 No No Edward syndrome
GBS ¼ group B streptococcus; PPROM ¼ preterm prelabor rupture of membrane.
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in the maternal genital tract and should theoretically be effective in
reducing neonatal infection. Therefore, it would be worthwhile to
consider giving ampicillin/amoxicillin prophylaxis to women pre-
senting with PPROM after 34 weeks and to women in whom the
GBS status is uncertain. Another limitation of our study is that it
was not a randomized controlled trial, and therefore there were
some differences between groups in terms of gestational age at
ROM; latency between ROM and delivery and gestational age at
delivery may have been confounding factors affecting the neonatal
outcomes. Hence, further research including randomized control
trials may be indicated to conﬁrm the superiority of ampicillin/
amoxicillin over erythromycin in the prophylaxis against GBS in
PPROM. In addition, women with PPROM who were not active GBS
carriers were not included in our study and their neonatal out-
comes were unknown. Therefore, whether the neonatal infections
other than GBS infection would be reduced by penicillins or
erythromycin remained uncertain. Further randomized controlled
trials are needed to evaluate the beneﬁts of antenatal ampicillin/
amoxicillin in PPROM cases.
Conclusion
GBS colonization is common inwomen presenting with PPROM.
However, most women are unaware of their GBS carriage status
before delivery. In view of the high incidence of erythromycin
resistance, erythromycin should not be the sole ﬁrst-line prophy-
lactic antibiotic for women presenting with PPROM. Instead, pen-
icillins such as ampicillin or amoxicillin should be used in active
GBS carriers and in women with unknown GBS carriage status as it
is more effective in reducing neonatal GBS infection.
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